| The Hippo pathway: immunity and cancer Z Taha, H J. Janse van Rensburg, X Yang Cancers 10 (4), 94, 2018 | 148 | 2018 |
| Characterization of critical determinants of ACE2–SARS CoV-2 RBD interaction EEF Brown, R Rezaei, TR Jamieson, J Dave, NT Martin, R Singaravelu, ... International Journal of Molecular Sciences 22 (5), 2268, 2021 | 36 | 2021 |
| Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry T Azad, R Singaravelu, Z Taha, TR Jamieson, S Boulton, MJF Crupi, ... Molecular Therapy 29 (6), 1984-2000, 2021 | 27 | 2021 |
| Implications for SARS-CoV-2 vaccine design: Fusion of spike glycoprotein transmembrane domain to receptor-binding domain induces trimerization T Azad, R Singaravelu, MJF Crupi, T Jamieson, J Dave, EEF Brown, ... Membranes 10 (9), 215, 2020 | 26 | 2020 |
| SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition T Azad, R Singaravelu, EEF Fekete, Z Taha, R Rezaei, R Arulanandam, ... Biosensors and Bioelectronics 180, 113122, 2021 | 25 | 2021 |
| Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy ME Wedge, VA Jennings, MJF Crupi, J Poutou, T Jamieson, A Pelin, ... Nature communications 13 (1), 1898, 2022 | 24 | 2022 |
| Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern ME Carter-Timofte, R Arulanandam, N Kurmasheva, K Fu, G Laroche, ... ACS infectious diseases 7 (11), 3034-3051, 2021 | 22 | 2021 |
| Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection S Boulton, J Poutou, NT Martin, T Azad, R Singaravelu, MJF Crupi, ... Molecular Therapy 30 (5), 1885-1896, 2022 | 19 | 2022 |
| Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer MJF Crupi, Z Taha, TJA Janssen, J Petryk, S Boulton, N Alluqmani, ... Frontiers in Immunology 13, 1029269, 2022 | 15 | 2022 |
| The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy R Arulanandam, Z Taha, V Garcia, M Selman, A Chen, O Varette, ... Communications Biology 3 (1), 254, 2020 | 15 | 2020 |
| Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen Z Taha, R Arulanandam, G Maznyi, E Godbout, ME Carter-Timofte, ... Molecular Therapy 30 (9), 2998-3016, 2022 | 7 | 2022 |
| Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy B Wong, A Bergeron, G Maznyi, K Ng, A Jirovec, HK Birdi, D Serrano, ... Molecular Therapy 31 (11), 3176-3192, 2023 | 6 | 2023 |
| Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy NT Martin, MJF Crupi, Z Taha, J Poutou, JT Whelan, S Vallati, J Petryk, ... Pharmaceuticals 16 (5), 709, 2023 | 3 | 2023 |
| CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX JT Whelan, R Singaravelu, F Wang, A Pelin, LA Tamming, G Pugliese, ... Frontiers in Immunology 13, 1050250, 2023 | 3 | 2023 |
| Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines N Alluqmani, A Jirovec, Z Taha, O Varette, A Chen, D Serrano, G Maznyi, ... Frontiers in immunology 13, 1032356, 2022 | 3 | 2022 |
| PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication M Geletu, Z Taha, PT Gunning, L Raptis Cancers 11 (2), 167, 2019 | 2 | 2019 |
| Effect of caveolin-1 on Stat3-ptyr705 levels in breast and lung carcinoma cells M Geletu, Z Taha, R Arulanandam, R Mohan, HH Assi, MG Castro, ... Biochemistry and Cell Biology 97 (5), 638-646, 2019 | 2 | 2019 |
| AT cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection S Boulton, J Poutou, R Gill, N Alluqmani, X He, R Singaravelu, MJF Crupi, ... Molecular Therapy-Methods & Clinical Development 31, 2023 | 1 | 2023 |
| Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice W Cheng, J Huang, XQ Fu, WY Tian, PM Zeng, Y Li, ZG Luo Molecular Therapy 31 (11), 3277-3289, 2023 | 1 | 2023 |
| Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus Z Taha, MJF Crupi, N Alluqmani, F Fareez, K Ng, J Sobh, E Lee, A Chen, ... Frontiers in Immunology 14, 1181014, 2023 | 1 | 2023 |
John BellProfessor of Medicine, University of OttawaVerified email at ohri.ca
